Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:43:14 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



Q:CRPOF - CEAPRO INC - http://www.ceapro.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CRPOF - Qnot subscribed0.1845    0.437  0.1146Apr 22Apr 2915 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-29 09:00U:CRPOFNews ReleaseCeapro Inc. Reports 2023 Financial Results and Operational Highlights
2024-03-28 07:55U:CRPOFNews ReleaseCeapro Receives Final Court Approval for Merger with Aeterna Zentaris
2024-03-12 14:11U:CRPOFNews ReleaseAeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
2024-02-26 07:30U:CRPOFNews ReleaseLeading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
2024-02-23 09:00U:CRPOFNews ReleaseCeapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
2024-02-15 17:50U:CRPOFNews ReleaseCeapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
2024-02-15 17:50U:CRPOFNews ReleaseAeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
2023-12-14 07:50U:CRPOFNews ReleaseAeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
2023-12-13 08:47U:CRPOFNews ReleaseCeapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
2023-11-29 09:05U:CRPOFNews ReleaseCeapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
2023-11-27 09:15U:CRPOFNews ReleaseCeapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
2023-11-07 08:05U:CRPOFNews ReleaseCeapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
2023-08-29 09:05U:CRPOFNews ReleaseCeapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
2023-08-25 09:05U:CRPOFNews ReleaseCeapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
2023-07-18 09:05U:CRPOFNews ReleaseCeapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
2023-07-05 08:45U:CRPOFNews ReleaseCeapro to Participate in the Virtual Investor Summer Spotlight Series
2023-06-07 09:05U:CRPOFNews ReleaseCeapro Announces Results of 2023 Shareholders ¢ € ™ Meeting